PHARMA
Temasek Invests US$800 Million In Verily
Singapore-based Temasek will invest in Alphabet's health-focused company Verily to commercialize healthcare solutions.
WuXi Acquires Biologics CRO HD Biosciences
WuXi AppTec strengthens its biologics capabilities with its acquisition of Shanghai-based HD Biosciences.
Eisai Joins Access Accelerated To Tackle Non-Communicable Diseases
Eisai will participate in a global partnership of pharmaceutical companies to help accelerate access to health care in low and middle-income countries.
Valeant Sells Cancer Business To China’s Sanpower For US$820 Million
In an attempt to reduce its debt, Valeant will sell its cancer vaccine business to Sanpower Group for US$819.9 million in cash.
Takeda Invests US$125 Million In Maverick’s T-Cell Platform
Maverick Therapeutics Inc. and Takeda will collaborate to develop a biologics platform for T-cell immunotherapy over the next five years.
WuXi NextCODE To Power Singapore’s Precision Medicine Initiative
WuXi NextCODE has been selected to install a massively scalable database, analytics and reporting suite for Singapore's precision medicine efforts.
Takeda & PvP Biologics To Develop Drugs Against Celiac Disease
Takeda Pharmaceuticals and PvP Biologics have signed an agreement to develop therapeutics targeting celiac disease.
Eisai & Keio University To Pursue Innovation In Dementia Drugs
The collaboration taps on Keio University's strengths in iPS technology and supercentenarian research.
NovogeneAIT To Establish Whole Genome Sequencing Center In Singapore
The whole genome sequencing center will support public research projects and super scale sequencing initiatives in Singapore and the region.
